Review of where psychedelic-assisted therapies stand in the clinic and in regulation

The question

Where do psychedelic-assisted therapies currently stand as psychiatric treatments, and what regulatory rules shape whether and how they can be used?

What they did

The authors wrote a narrative review, meaning they selected and discussed existing evidence rather than following a formal systematic search method. They drew on phase II and phase III clinical trials (mid- and late-stage human trials), documents from drug regulators, and international drug policy frameworks. The compounds covered were ketamine and esketamine, MDMA, psilocybin, LSD, DMT and 5-MeO-DMT, and ibogaine. Conditions covered included major depressive disorder, treatment-resistant depression, PTSD, anxiety disorders and substance use disorders.

What they found

The authors report that late-stage trials support the potential of these therapies for people with high needs who have not responded to standard treatments. They argue that these treatments are unlikely to work as ordinary take-home prescriptions, and would instead need to be delivered by trained specialists alongside psychotherapy, with ethical and regulatory safeguards in place. They also describe differences in scheduling rules, approval paths and access mechanisms across the United States, the European Union and other jurisdictions. No pooled effect sizes, response rates or participant numbers are given in the abstract.

The fine print

This is a narrative review, so the authors chose which studies to discuss and no formal method for selecting or weighing evidence is described. The abstract reports no numbers, no effect sizes and no participant totals, so readers cannot judge the strength of the underlying trials from it. The ‘expert opinion’ section is interpretation, not data. This summary is based on the abstract only.

What it means

The review’s central point is practical rather than clinical: even where trial results look promising, questions about long-term safety, staffing, cost, fair access and legal responsibility still need answers before these treatments could be offered widely.

Evidence grade: Very low. This is a narrative review and expert opinion piece: it summarizes other people’s trials without a systematic search, pooled analysis or any reported numbers.

This summary is based on the study’s published abstract.